Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

Objectives: To develop a new index for disease activity in ankylosing spondylitis (ASDAS) that is truthful, discriminative and feasible, and includes domains/items that are considered relevant by patients and doctors. Methods: Eleven candidate variables covering six domains of disease activity, selected by ASAS experts in a Delphi exercise, were tested in a three-step approach, similar to the methodology used for the disease activity score in rheumatoid arthritis. Data on 708 patients included in ISSAS (International Study on Starting tumour necrosis factor blocking agents in Ankylosing Spondylitis) were used. Cross validation was carried out in the OASIS cohort (Outcome in Ankylosing Spondylitis International Study). Results: Principal component analysis disclosed three factors with eigenvalues >0.75: patient assessments, peripheral joint assessments and acute phase reactants. Discriminant function analysis resulted in a correct classification in ∼72% of the cases (prior probability ∼50%). Regression analysis resulted in an index with five variables (total back pain, patient global assessment, duration of morning stiffness, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)). Three additional candidate indices were designed using similar methodology while omitting either ESR or CRP or patient global assessment. All four scores correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; r = 0.67–0.80), patient (0.58–0.75) and physician’s global assessment (0.41–0.48) of disease activity. All four candidate ASDAS indices performed better than BASDAI or single-item variables in discriminating between high and low disease activity state, according to doctors as well as patients in the OASIS cohort. Conclusion: The first steps in the development of a new assessment tool of disease activity in AS derived four candidate indices with good face and construct validity, and high discriminant capacity.

[1]  L. Klareskog,et al.  Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description , 2004, Annals of the rheumatic diseases.

[2]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .

[3]  D. M. van der Heijde,et al.  Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. , 2004, Arthritis and rheumatism.

[4]  W. Maksymowych,et al.  Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. , 2004, Journal of Rheumatology.

[5]  K L Haywood,et al.  Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. , 2002, Rheumatology.

[6]  Jacob Cohen Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[7]  D. M. van der Heijde,et al.  Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. , 2008, Arthritis and rheumatism.

[8]  M. Dougados,et al.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.

[9]  P. Tugwell,et al.  OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.

[10]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[11]  S. van der Linden,et al.  Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[12]  D. M. van der Heijde,et al.  Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. , 2008, Arthritis and rheumatism.

[13]  P. Tugwell,et al.  The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.

[14]  M. A. van 't Hof,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.

[15]  M. Dougados,et al.  Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. , 2005, Rheumatology.

[16]  M. Dougados,et al.  An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis , 2006, Annals of the rheumatic diseases.

[17]  P. Lachenbruch Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .